Commitments and Contingencies (Details Narrative) |
3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 04, 2022
USD ($)
|
Mar. 03, 2022
USD ($)
|
Dec. 29, 2021
USD ($)
|
Dec. 02, 2021
USD ($)
|
Nov. 19, 2021
ft²
|
Aug. 06, 2021
USD ($)
|
Mar. 26, 2021
USD ($)
|
Oct. 05, 2020 |
Mar. 31, 2021
USD ($)
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2021
USD ($)
|
|
| Loss Contingencies [Line Items] | |||||||||||
| Project fees | $ 2,100,000 | ||||||||||
| Initial payment | $ 191,527 | $ 541,527 | |||||||||
| Periodic payment to be made | 191,527 | ||||||||||
| Final payment | 192,470 | ||||||||||
| Other Commitments, Description | On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At December 31, 2021, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $7.5 million was incurred at that date and an additional $5.5 million is in process during fiscal year 2022. | ||||||||||
| Received upfront payment | 200,000 | ||||||||||
| Annual maintanance fee | $ 100,000 | ||||||||||
| Royalty fee percentage | 0.04 | ||||||||||
| Annual royalty payments | $ 250,000 | ||||||||||
| Performance milestone payments | 3,100,000 | $ 3,100,000 | |||||||||
| Sales milestone payments | 1.0 | 1,000,000.0 | |||||||||
| Gross sales | 250,000,000 | 250,000,000 | |||||||||
| Sales revenue | 5.0 | $ 5.0 | |||||||||
| Cummulative gross sales | 500,000,000 | $ 500 | |||||||||
| Upfront license fee | $ 20,000 | ||||||||||
| License maintenance fee, receivable | 5,000 | ||||||||||
| [custom:MaintananceFee] | $ 2.0 | ||||||||||
| Aimmune Therapeutics Inc [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Area of Land | ft² | 4,500 | ||||||||||
| Lessee, Operating Sublease, Option to Extend | commencement date of January 1, 2022 and maturing on June 30, 2024 | ||||||||||
| Minimum [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Annual royalty payments | 250,000 | ||||||||||
| [custom:NetSalesPercentage] | 0.025 | ||||||||||
| Maximum [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| [custom:NetSalesPercentage] | 0.05 | ||||||||||
| Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Commitment amount for services, total | 13,000,000.0 | ||||||||||
| Commitment cost incurred | 7,500,000 | ||||||||||
| Compensation cost expected to be incurred in future | $ 5,500,000 | ||||||||||
| Sheffield Properties [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Litigation Settlement, Expense | $ 100,000 | ||||||||||
| Subsequent Event [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Litigation Settlement, Expense | $ 425,000,000,000 | $ 400,000 | |||||||||